Analysts Issue Forecasts for DWTX Q1 Earnings

Dogwood Therapeutics, Inc (NASDAQ:DWTX) – Stock analysts at Zacks Research issued their Q1 2026 earnings per share (EPS) estimates for Dogwood Therapeutics in a research note issued to investors on Monday, March 23rd. Zacks Research analyst D. Bautz anticipates that the company will post earnings per share of ($0.13) for the quarter. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($6.43) per share. Zacks Research also issued estimates for Dogwood Therapeutics’ Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at ($0.47) EPS and FY2028 earnings at ($0.40) EPS.

A number of other equities analysts also recently issued reports on DWTX. Wall Street Zen downgraded Dogwood Therapeutics to a “strong sell” rating in a report on Saturday, December 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Monday, December 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Dogwood Therapeutics in a report on Friday, February 20th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $12.00.

Dogwood Therapeutics Price Performance

Shares of NASDAQ DWTX opened at $2.08 on Thursday. The business has a 50-day moving average of $2.92 and a two-hundred day moving average of $4.59. The company has a market capitalization of $69.47 million, a price-to-earnings ratio of -0.11 and a beta of 1.90. Dogwood Therapeutics has a 1 year low of $2.07 and a 1 year high of $9.50.

Dogwood Therapeutics (NASDAQ:DWTX) last posted its earnings results on Wednesday, March 18th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($1.22) by $0.96.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 9.05% of the company’s stock.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.